Introduction
The main challenge for cancer treatment still remains the control of metastasis. Metastasis is a multistep process initiated by tumor cells which escape from a primary tumor and enter the blood circulation or the lymphatic system. While large numbers of tumor cells may enter the blood stream from a primary lesion, only very few survive the host defense mechanisms, arrest in the vasculature of distant organs and finally form metastatic foci. There is increasing evidence that platelet activity may facilitate this process. Platelets have been associated with cancer since 1865, when the French physician Armand Trousseau discovered and described the association of excessive blood coagulation with cancer progression [reviewed in 1].
Although the initial clinical observations of migratory thromboses and platelet-rich microthrombi are mostly associated with gastrointestinal malignancies, the majority of advanced cancer patients develop thrombotic abnormalities and hypercoagulable state [1] [2] [3] [4] .
The clinical correlation between platelet dysfunction and cancer progression is supported by a large body of evidence obtained from several animal models [e.g. 5, 6] . Experimentally induced thrombocytopenia (depletion of platelets) was shown to reduce the development of metastasis both in transplant and syngeneic mouse tumor models [7] . Various human and animal tumor cells were found to be capable of inducing platelet aggregation and activation [e.g. 3, [8] [9] [10] [11] . Any interference in platelet-tumor cell interactions with anti-platelet agents has consistently demonstrated potent anti-metastatic effects [reviewed in 10, 12] . In this article, the mechanisms of platelet contribution to metastasis are reviewed and possible perspectives for therapeutic application are discussed.
Physiological functions of platelets
Platelets are highly reactive cellular effectors of hemostasis and thrombosis in humans and other mammals. Vessel wall injury or thrombus formation stimulates platelets to adhere to subendothelial matrix and to undergo activation leading to aggregation and release of mediators for further aggregation, angiogenesis and inflammation. Together with a display of many adhesion molecules, platelets mediate the subsequent recruitment of inflammatory cells and enable multidirectional interactions among leukocytes, endothelial cells, subendothelial matrix, and other platelets. However, in part the same processes cause adverse clinical events associated with thrombotic vessel occlusion [13] .
Platelets are small anucleate cell fragments derived from megakaryocytes in the bone marrow.
The platelet membrane contains a dense layer of glycoproteins (GPs) and integrins, which mediate their adhesive properties leading also to aggregation. Although most of the platelets never become activated or adherent in their life time, their exposure to activating molecules, e.g. von Willenbrand Factor (vWF), collagen etc. causes a rapid activation resulting in adhesion and aggregation [13] . The principal platelet adhesive receptor is GP Ib/IX/V complex which upon binding to vWF both induces platelet adhesion and activation. Platelets bound to vWF undergo activation of the GPIIb/IIIa receptor which facilitates high affinity binding to fibrinogen. Activation of platelets results in surface expression of adhesion molecules responsible for an enhanced and rapid adherence. In addition, activation of platelets induces shape change, which is associated with a rearrangement of cytoskeletal proteins resulting in actin polymerization and extension of filapodia [14] . Adhesive properties of platelets have to be strictly regulated to maintain function during hemostasis.
Platelets function beyond hemostasis
The activity of platelets is also controlled by 7-transmembrane receptor family consisting of thrombin, prostaglandin and chemokine receptors [for review see 13,14] . Protease activation receptor-1 (PAR-1) and PAR-4 are specifically activated by thrombin. After stimulation, platelets also release various substances contributing to the local activation and additional recruitment of platelets and leukocytes. Platelets contain two types of distinct secretory vesicles, α-granules and dense granules. Upon activation, these granules fuse with the cell membrane and release a number of bioactive molecules into the local periphery and simultaneously expose adhesion receptors on platelets surface [15] . α-Granules contain large proteins and adhesion molecules, like P-selectin, GPs, growth factors, and thrombospondin.
Dense granules contain small molecules including serotonin, Calcium ions, ADP and ATP, which help recruiting other platelets [16] . Platelets synthesize and release thromboxane A 2 on stimulation with collagen, thrombin or ADP, thereby further promote recruitment and activation of platelets [17] .
Platelets, in addition to exerting hemostatic activity can also contribute to immunity and inflammation. Activated platelets release a number of secretory molecules including chemokines, cytokines, growth factors, coagulation factors and metalloproteinases [18, 19] . To the most potent chemokines secreted by platelets belong: CCL5 (also known as RANTES), CCL3 (macrophage inflammatory protein -1), and CXCL4 (platelet factor 4, PF4) [18] .
Platelet's CCL5 binds to endothelium and is the primary chemokine responsible for a recruitment of monocytes and T cells [20, 21] . The surface expression of CD40 ligand on activated platelets induces rapid activation of endothelial cells associated with secretion of chemokines and expression of adhesion molecules responsible for recruitment of leukocytes [22, 23] . Detection of functional protein synthesis in platelets will probably lead to identification of further novel biological activities [24] . The messenger RNA profiling of human platelets, together with a validation of platelet protein synthetic activity can further modulate platelet phenotype and function based on a stimuli and a cellular context [25, 26] .
Platelets during cancer progression -clinical evidence
Hemostatic abnormalities associated with human cancer are common, yet diverse. In some cases, patients with occult malignancy develop deep vein thrombosis or pulmonary embolism [1] . In other cases, clinical findings may relate to disseminated intravascular coagulation (DIC) or to thrombohemorrhagic syndromes, which are commonly referred to as cancer coagulopathy [2, 27] . The pathophysiology of thrombosis in cancer is complex but likely includes all aspects of Virchow's triad: stasis of blood, vascular trauma and hypercoagulability of blood itself [1, 4] . The clinical evidence for higher platelet counts, high platelet turnover, and the presence of activated platelets in the circulation generally indicates poor prognosis in most cancers [3, [28] [29] [30] . Although substantial clinical, epidemiologic and pathologic evidence validate the cancer associated thrombosis, this phenomenon has been considered an epiphenomenon of cancer progression for a long time. However, there is large body of evidence that platelets not only contribute to coagulation but rather promote cancer development and progression, through directly effecting tumor growth, angiogenesis and metastatic dissemination [1, 9, [31] [32] [33] [34] .
Platelets during metastasis -experimental evidence
The clinical correlation between platelets dysfunction and cancer progression was further 
Platelet aggregation and Trousseau's syndrome
Originally, Trousseau's syndrome describes the formation of venous and arterial platelet-rich microthrombi with secondary microangiopathic hemolytic anemia, and a frequent association with mucinous carcinomas [2] . Nowadays, Trousseau's syndrome applies to thrombotic events preceding the detection of an occult cancer. Based on this broader definition of Trousseau's syndrome, several molecular mechanisms regulating tumor cell induced platelet aggregation were described [65-67]. Since thrombosis occurs in the setting of occult carcinomas, it is reasonable to expect that a factor produced by tumor cells is being released into the bloodstream, which is responsible for thrombotic propensity [2] . There were two main studies investigating Trousseau's syndrome in animal models [6, 68] . In the first model, purified carcinoma mucins, free of any TF, were shown to induce platelet-rich microthrombi formation in vivo [68] . Furthermore, these microthrombi in a mouse model were dependent on the presence of both P-and L-selectin, strongly indicating that a cross-talk between leukocytes and platelets is required for this process. Platelet aggregates, formed on the carcinoma mucin backbone, were shown to be thrombin independent. Thus thrombin generation is not a proximal step leading to formation of platelet-rich microthrombi, but rather an event dependent on selectin-mediated interactions between platelets and leukocytes. These observations are in agreement with the carcinoma mucin mediated activation of leukocytes through L-selectin signaling, which leads to activation of platelets by a yet unidentified mediator [68] . Finally, the positive effect of heparin treatment in Trousseau's syndrome patients may simply reflect the capacity of heparin to efficiently block P-and L-selectin mediated interactions. In the second model, targeting of activated human MET oncogene to the mouse liver resulted in slowly progressing hepatocarcinogenesis [6] . Prior to detection of dysplastic nodules all animals developed thrombohemorrhagic syndrome, similar to the symptoms observed in Trousseau's syndrome.
Platelet-mediated angiogenesis and tumor growth
Platelets can exert direct stimulatory action on tumor cells and promote angiogenesis. with the tumor burden [72] . Analysis of platelets from breast cancer patients revealed a markedly higher secretion of VEGF upon activation when compared to platelets from healthy donors [73] . Large numbers of activated platelets were detected in soft tissue tumors, which were associated with abundant expression of VEGF, and ongoing angiogenesis [74] . It is conceivable that VEGF secreted by platelets stimulates angiogenesis by the local activation of endothelium in vivo, since platelets were shown to stimulate endothelial proliferation in vitro [72] . The contribution of platelets to tumor cell-induced angiogenesis has been thoroughly reviewed elsewhere [34, 75] .
Recently, platelet-derived bioactive lipid -lysophosphatidic acid (LPA) was found to have a growth-factor-like signaling properties [76] . LPA is a water soluble biolipid consisting of a phosphoglycerol backbone with only one fatty acid chain [77] . Upon generation, LPA exerts its activity either in autocrine or paracrine fashion, on G protein-coupled receptors family of LPA receptors [78] . Activation of downstream signaling pathways leads to cell proliferation, increased survival and enhanced migration. Boucharaba and colleagues have identified platelet-derived LPA as an enhancer of bone metastasis by breast and ovarian cancer cells [76] .
Platelets modulate degradation and further remodeling of basement membrane and ECM components, which can serve angiogenesis and tumor cell invasion [79] . Activated platelets secrete gelatinase A [80] , heparanase [81] , and induce the release of gelatinase and urokinase (u-PA) by endothelial cells and tumor cells in vitro [82] . The role of platelet-derived microparticles (PMV), which are circular fragments shed by activated platelets, was analyzed for its potential to contribute to metastasis [83, 84] . PMV were shown to adhere to tumor cells and initiate phosphorylation of mitogen-activated protein kinase p42/44 and expression of membrane type 1-MMP [83] . Addition of PMV to breast cancer cells induced expression of MMP-9 and thereby increased tumor cell transmigration in vitro [84] . In another breast cancer model, platelets promoted invasion of MCF7 cells, which was correlated with an increase of MMP-9 level produced by tumor cells [85] .
Platelets as therapeutic targets for anti-cancer therapies
Based on the understanding of platelet-tumor cell aggregate formation, potential inhibitors of cancer progression are being explored [reviewed in [10, 12] . Platelets adhesion molecules are involved in mediation of platelet-tumor cell interactions. Since GPIIb/IIIa complex was convincingly shown to mediate this process, platelets antagonist based on its inhibition are being tested [5] . The antagonists of GPIIb/IIIa can be divided into RGD-mimicking nanopeptides and monoclonal antibodies binding this complex. Intravenous injection of monoclonal antibody (e.g. Abciximab) reduced tumor cell induced platelet aggregations and demonstrated antineoplastic effects [86] . Similarly, small molecule oral antagonist of GPIIb/IIIa was shown to efficiently reduce platelet aggregation and metastasis [87] .
Although P-selectin mediated platelet-tumor cell interactions are well recognized, the specific inhibition of P-selectin in cancer has not been explored [88, 89] . Heparin is a highly sulfated glycosaminoglycan that has been in clinical use as an anticoagulant for many years. Besides its known anti-coagulant activity, heparin can also efficiently bind to P-and L-selectin and was shown to abrogate cancer cell interactions with platelets, thereby attenuating metastasis [39,56,59, 90, 91] . Furthermore, we could show that heparin derivatives without any anticoagulant activity, but containing P-selectin binding activity attenuate metastasis as efficiently as native heparin [91] . This finding strongly indicates that inhibition of P-selectin is one of the main cancer inhibitory activities of heparin [91] . Based on the encouraging observations with heparin treatment evaluated in retrospective studies, several recent prospective clinical trials have been performed to study this phenomenon [92] [93] [94] [95] . The promising results from the clinical studies, primarily in earlier stage patients together with the experimental evidence suggests that heparin treatment directly affect the metastasis rather than by simple inhibition of coagulation [35] . While targeting platelet contribution to cancer progression is actively being pursued, there is at present no clinical trial in cancer patients. A major concern in clinical trials of platelet inhibitors in cancer is the possibility that normal platelet function will be limited leading to bleeding complications.
Expert opinion
The 
Five-year view -future directions
The complexity of molecular mechanisms that mediate platelet-tumor cell interactions makes a pharmacological inhibition of these interactions rather challenging. In particular, the lack of selectivity poses a major problem in targeting platelets. Although specific inhibition of platelet functions during cancer thrombosis is likely not possible, accumulated evidence from experimental models suggests possible future directions. A first step is to find a cancer type, where cancer progression is shown to be dependent on platelet activation. Platelet microthrombi formation associated with Trousseau's syndrome is often found in mucinproducing carcinomas, yet the underlying mechanism remains unclear [2] . The current evidence that carcinoma mucins can induce platelet aggregation similar to Trousseau' syndrome [68] indicates that platelet activation plays an important role in mucin-carrying carcinomas. The formation of platelet aggregates was shown to be dependent on P-selectin, which effectively binds to soluble mucins or mucin-carrying carcinoma cells. These observations make P-selectin a possible candidate for cancer specific therapy. Another issue is to limit the inhibition to affect mostly, if not exclusively, cancer associated mechanisms. This problem will likely be a common one to be encountered by any inhibitor of molecules presented by activated platelets. The main question is whether prolonged inhibition of Pselectin will be associated with deleterious side effects in cancer patients. Intriguingly, there is clinical experience with prolonged inhibition of P-selectin. Therapeutic concentrations of unfractionated heparin used in clinical application were found to be sufficient to effectively inhibit P-selectin [101] . A prolonged application of unfractionated heparin for anticoagulation, commonly used also in cancer patients, has inadvertently achieved significant P-selectin inhibition. Thus P-selectin represents a promising candidate for therapeutic 
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